Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

atoplab.com
 

Enter Stock Symbol:  

Catabasis Pharmaceuticals Inc. (CATB)

0.64 -0.01 (-1.54%)

11-14 16:00

Open:

0.6413

Pre. Close:

0.65

High:

0.6699

Low:

0.62

Volume:

280,540

Market Cap:

45M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

0.671 - 0.674

0.674 - 0.677

Low:

0.611 - 0.615

0.615 - 0.619

Close:

0.633 - 0.639

0.639 - 0.645

Technical analysis  (as of: 2018-11-14 4:30:49 PM)

Overall:

      

Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 0.81     One year: 0.87

Support:

Support1: 0.62    Support2: 0.51

Resistance:

Resistance1: 0.70    Resistance2: 0.75

Pivot:

0.66

Moving Averages:

MA(5): 0.67     MA(20): 0.67

MA(100): 0.74     MA(250): 1.28

MACD:

MACD(12,26): -0.02     Signal(12,26,9): -0.02

%K %D:

%K(14,3): 31.11     %D(3): 46.14

RSI:

RSI(14): 41.23

52-Week:

High: 2.38  Low: 0.61  Change(%): -61.2

Average Vol(K):

3-Month: 101105  10-Days 30686

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CATB has closed above bottom band by 25.7%. Bollinger Bands are 61.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to CATB's normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-11-13T14:45:07-05:00
Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q3 2018 Results - Earnings Call Transcript

2018-11-13T10:04:06-05:00
Catabasis Pharma inks collaboration to explore potential of edasalonexent in Duchenne and Becker muscular dystrophies

2018-11-13T10:01:53-05:00
Catabasis Pharmaceuticals 2018 Q3 - Results - Earnings Call Slides

2018-11-13T08:05:00-05:00
Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress

2018-11-13T07:45:00-05:00
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology

Shares Out. (M)

71.04

Shares Float (M)

70.53

% Held by Insiders

1.70

% Held by Institutions

74.90

Shares Short (K)

Shares Short Prior Month (K)

Stock Financials

EPS

-1.040

EPS Est. Current Year

-1.390

EPS Est. Next Year

-1.100

EPS Est. Next Quarter

-0.330

Forward EPS

-1.190

Book Value (p.s.)

1.090

PEG Ratio

Profit Margin

Operating Margin

-5157.80

Return on Assets (ttm)

-65.3

Return on Equity (ttm)

-79.1

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.096

Qtrly Earnings Growth

Operating Cash Flow (M)

-25.47

Levered Free Cash Flow (M)

-14.70

Valuation

P/E

-0.62

P/E Growth Ratio

-0.03

P/BV

0.59

P/S

2273280000.00

P/CF

-1.79

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.